BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang CH, Guo ZY, Chen ZT, Zhi XT, Li DK, Dong ZR, Chen ZQ, Hu SY, Li T. TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection. Sci Rep 2015;5:12366. [PMID: 26190376 DOI: 10.1038/srep12366] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Exposito F, Villalba M, Redrado M, de Aberasturi AL, Cirauqui C, Redin E, Guruceaga E, de Andrea C, Vicent S, Ajona D, Montuenga LM, Pio R, Calvo A. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Letters 2019;453:21-33. [DOI: 10.1016/j.canlet.2019.03.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
2 Zhang Q, Wang JY, Yan W, Wang DD, Yang SJ, Zhou SY, Zhong SL, Tang JH. Clinical and pathological significance of Homo sapiens ceramide synthase 2 (CerS-2) in diverse human cancers. Biosci Rep 2019;39:BSR20181743. [PMID: 30988071 DOI: 10.1042/BSR20181743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Li T, Wang SK, Zhi XT, Zhou J, Dong ZR, Zhang ZL, Sun HC, Ye QH, Fan J. Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma. Sci Rep 2016;6:28229. [PMID: 27320390 DOI: 10.1038/srep28229] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Li XM, Liu WL, Chen X, Wang YW, Shi DB, Zhang H, Ma RR, Liu HT, Guo XY, Hou F, Li M, Gao P. Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancer. Int J Mol Med 2017;39:927-35. [PMID: 28259959 DOI: 10.3892/ijmm.2017.2893] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
5 Murray AS, Varela FA, List K. Type II transmembrane serine proteases as potential targets for cancer therapy. Biol Chem 2016;397:815-26. [PMID: 27078673 DOI: 10.1515/hsz-2016-0131] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
6 Wu Z, He L, Yang L, Fang X, Peng L. Potential Role of NEU1 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis. Front Mol Biosci 2021;8:651525. [PMID: 34513919 DOI: 10.3389/fmolb.2021.651525] [Reference Citation Analysis]
7 Mitschke J, Burk UC, Reinheckel T. The role of proteases in epithelial-to-mesenchymal cell transitions in cancer. Cancer Metastasis Rev 2019;38:431-44. [PMID: 31482486 DOI: 10.1007/s10555-019-09808-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
8 Ruan H, Wang T, Yang C, Jin G, Gu D, Deng X, Wang C, Qin W, Jin H. Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma. Sci Rep 2016;6:32421. [PMID: 27581744 DOI: 10.1038/srep32421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Wang J, Leng X, Wang G, Wan X, Cao H. The construction of intrahepatic cholangiocarcinoma model in zebrafish. Sci Rep 2017;7:13419. [PMID: 29042681 DOI: 10.1038/s41598-017-13815-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
10 Mahati S, Bolati D, Yang Y, Mao R, Zhang H, Bao Y. TMPRSS4 promotes cancer stem cell traits by regulating CLDN1 in hepatocellular carcinoma. Biochem Biophys Res Commun 2017;490:906-12. [PMID: 28651932 DOI: 10.1016/j.bbrc.2017.06.139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, Shi K, Yan YC, Yan LJ, Yao CY, Chen ZQ, Zhi XT, Li T. TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology 2020;72:923-39. [PMID: 31867749 DOI: 10.1002/hep.31076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
12 Villalba M, Diaz-Lagares A, Redrado M, de Aberasturi AL, Segura V, Bodegas ME, Pajares MJ, Pio R, Freire J, Gomez-Roman J, Montuenga LM, Esteller M, Sandoval J, Calvo A. Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients. Oncotarget 2016;7:22752-69. [PMID: 26989022 DOI: 10.18632/oncotarget.8045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
13 Xiao H, Zhang Z, Peng D, Wei C, Ma B. Type II transmembrane serine proteases 4 (TMPRSS4) promotes proliferation, invasion and epithelial-mesenchymal transition in endometrial carcinoma cells (HEC1A and Ishikawa) via activation of MAPK and AKT. Anim Cells Syst (Seoul) 2021;25:211-8. [PMID: 34408809 DOI: 10.1080/19768354.2021.1944311] [Reference Citation Analysis]
14 Song SK, Park MG, Park SK, Chung CW, Park Y. MicroRNAs associated with microvascular invasion in hepatocellular carcinoma and their prognostic impacts in patients undergoing hepatic resection. Oncol Lett 2019;18:6293-303. [PMID: 31788107 DOI: 10.3892/ol.2019.10987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, Zhou JM, Boulware DC, Kim J, Haura EB, Morse DL. Cell-surface marker discovery for lung cancer. Oncotarget 2017;8:113373-402. [PMID: 29371917 DOI: 10.18632/oncotarget.23009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
16 Liang Y, Yang Y, Guo R, Gao S, Guo X, Li D, Wang M, Koseki H, Li X. PCL2 regulates p53 stability and functions as a tumor suppressor in breast cancer. Science Bulletin 2018;63:629-39. [DOI: 10.1016/j.scib.2018.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Villalba M, Redin E, Exposito F, Pajares MJ, Sainz C, Hervas D, Guruceaga E, Diaz-Lagares A, Cirauqui C, Redrado M, Valencia K, de Andrea C, Jantus-Lewintre E, Camps C, Lopez-Lopez R, Lahoz A, Montuenga L, Pio R, Sandoval J, Calvo A. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Sci Rep 2019;9:15400. [PMID: 31659178 DOI: 10.1038/s41598-019-51066-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Wang Z, Qu L, Deng B, Sun X, Wu S, Liao J, Fan J, Peng Z. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling. Sci Rep 2016;6:33205. [PMID: 27628214 DOI: 10.1038/srep33205] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
19 Zhao XF, Yang YS, Gao DZ, Park YK. TMPRSS4 overexpression promotes the metastasis of colorectal cancer and predicts poor prognosis of stage III-IV colorectal cancer. Int J Biol Markers 2021;36:23-32. [PMID: 34595980 DOI: 10.1177/17246008211046368] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jiang J, Chen Y, Dong T, Yue M, Zhang Y, An T, Zhang J, Liu P, Yang X. Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway. Oncol Lett 2019;17:4505-13. [PMID: 30944640 DOI: 10.3892/ol.2019.10123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zeng P, Zhang P, Zhou LN, Tang M, Shen YX, Jin J, Zhu YQ, Chen MB. TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis. Oncotarget 2016;7:76327-36. [PMID: 27344186 DOI: 10.18632/oncotarget.10153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Villalba M, Exposito F, Pajares MJ, Sainz C, Redrado M, Remirez A, Wistuba I, Behrens C, Jantus-Lewintre E, Camps C, Montuenga LM, Pio R, Lozano MD, de Andrea C, Calvo A. TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. J Clin Med 2019;8:E2134. [PMID: 31817025 DOI: 10.3390/jcm8122134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Zhang Y, Zhang Z, Ma J, Pu J, Hou P, Yang Q. High-accuracy Detection of Preoperative Thyroid Nodules Using Combination of BRAFV600E Mutation and TMPRSS4 mRNA Level. Arch Med Res 2018;49:365-72. [PMID: 30518486 DOI: 10.1016/j.arcmed.2018.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Yan YC, Meng GX, Ding ZN, Liu YF, Chen ZQ, Yan LJ, Yang YF, Liu H, Yang CC, Dong ZR, Hong JG, Li T. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies. J Cancer 2022;13:88-101. [PMID: 34976173 DOI: 10.7150/jca.65574] [Reference Citation Analysis]
25 Dong ZR, Chen ZQ, Yang XY, Ding ZN, Liu KX, Yan LJ, Meng GX, Yang YF, Yan YC, Yao SY, Yang CC, Zhi XT, Li T. RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival. J Cancer 2021;12:3827-40. [PMID: 34093791 DOI: 10.7150/jca.56167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Dong ZR, Zhou W, Sun D, Yan YC, Yang CC, Yang YF, Li HC, Zhi XT, Li T. Role of the E3 Ubiquitin Ligase TRIM4 in Predicting the Prognosis of Hepatocellular Carcinoma. J Cancer 2020;11:4007-14. [PMID: 32368282 DOI: 10.7150/jca.37164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]